Abstract
Objectives
To investigate the effects of the selective cyclooxygenase-2 (COX-2) inhibitor etodolac
on prostate cancer cell lines in vitro and in vivo and on E-cadherin expression in
prostate cancer cells.
Methods
We evaluated the cytotoxicity of etodolac on the three prostate cancer cell lines
LNCaP, C4-2, and PC-3. We also performed quantitative real-time polymerase chain reaction
to measure the mRNA expression of COX-2, Bcl-2, and E-cadherin in these cell lines
after etodolac treatment. In addition, we investigated the in vivo antitumor effects
of etodolac on a human prostate cancer xenograft model.
Results
Etodolac exhibited significant antitumor effect in vivo and in vitro. The cytotoxicity
of etodolac in LNCaP and C4-2 was markedly increased at a dose of 1000 nM in a time-dependent
and dose-dependent manner. In the in vivo tumor growth study, the etodolac-treated
mice exhibited more significant cytotoxicity than the phosphate-buffered saline-treated
mice. Expression of E-cadherin after etodolac treatment tended to increase and that
of Bcl-2 to decrease, but the expression of COX-2 had no definite tendency.
Conclusions
The COX-2 inhibitor etodolac exhibited an antitumor effect on prostate cancer cell
lines in vitro and in vivo, and it might be useful for the treatment of hormone-resistant
prostate cancer.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.Cancer Res. 1998; 58: 362-366
- NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.Cancer Res. 1998; 58: 4245-4249
- Cancer research.Science. 2001; 291: 581-582
- Cyclooxygenase in biology and disease.FASEB J. 1998; 12: 1063-1073
- Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2.Cell. 1995; 83: 493-501
- Host cyclooxygenase-2 modulates carcinoma growth.J Clin Invest. 2000; 105: 1589-1594
- Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.J Biol Chem. 2001; 276: 18563-18569
- Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells.Adv Enzyme Regul. 2001; 41: 221-235
- Etiology, epidemiology, and prevention of carcinoma of the prostate.in: Walsh P.C. Retik A.B. Vaughan Jr, E.D. 7th ed. Campbells’ Urology. vol 3. WB Saunders, Philadelphia1998: 379-386
- Target to apoptosis.Prostate. 1997; 32: 284-293
- LNCaP model of human prostatic carcinoma.Cancer Res. 1983; 43: 1809-1818
- Establishment and characterization of a human prostatic carcinoma cell line (PC-3).Invest Urol. 1979; 17: 16-23
- Androgen-repressed phenotype in human prostate cancer.Proc Natl Acad Sci USA. 1996; 93: 15152-15157
- Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.Cancer Res. 1994; 54: 2577-2581
- Assessment of the Alamar Blue assay for cellular growth and viability in vitro.J Immunol Methods. 1997; 204: 205-208
- A COX-2 promoter-based replication-selective adenoviral vector to target the COX-2-expressing human bladder cancer cells.Clin Cancer Res. 2004; 10: 4342-4348
- TSH receptor status of thyroid neoplasms—Taqman RT-PCR analysis of archival material.J Pathol. 1999; 188: 87-92
- Demonstration of rat CAR bacillus using a labeled streptavidin biotin (LSAB) method.J Vet Med Sci. 1996; 58: 1219-1221
- Expression of cyclooxygenase-2 protein in gastric adenocarcinoma.J Surg Oncol. 1998; 69: 168-172
- Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues.FEBS Lett. 1993; 330: 156-160
- Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma.Prostate. 2000; 42: 73-78
- Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.Clin Exp Metastasis. 1999; 17: 687-694
- Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines.Int J Urol. 2001; 8: S35-S39
- Overcoming bcl-2- and p53-mediated resistance in prostate cancer.Semin Oncol. 1999; 26: 112-116
- The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.J Biol Chem. 2000; 275: 11397-11403
- Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac.Int J Cancer. 2001; 91: 894-899
- Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.J Urol. 2003; 170: 985-989
- Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas.Cancer. 2001; 92: 2786-2795
- Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines.Gastroenterology. 2002; 37: 896-904
Article info
Publication history
Accepted:
June 10,
2005
Received:
November 20,
2004
Identification
Copyright
© 2005 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
